ArticleBlood2012
Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression.
Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 84 citations in OpenAlex.
- Investigation of the protective effect of beta caryophyllene against indomethacin-induced gastric ulcer in rats: in vivo and in vitro study.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Electroacupuncture exerts antipruritic and anti-inflammatory effects on atopic dermatitis by activating CB2 receptor.Chinese medicine · 2025Article
- Foxq1 activates CB2R with oleamide to alleviate POCD.Brain pathology (Zurich, Switzerland) · 2025Article
- The effect of cannabinoid type Ⅱ receptor on the excitability of substantia nigra dopaminergic neurons.Frontiers in pharmacology · 2025Article
- Proteolytic Vesicles Derived fromBiomedicines · 2024Article
- Imaging and Genetic Tools for the Investigation of the Endocannabinoid System in the CNS.International journal of molecular sciences · 2023Review
- Role of the endocannabinoid system in the pathophysiology of endometriosis and therapeutic implications.Journal of cannabis research · 2022Review
- The Synthetic Cannabinoid URB447 Exerts Antitumor and Antimetastatic Effect in Melanoma and Colon Cancer.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Cannabis suppresses antitumor immunity by inhibiting JAK/STAT signaling in T cells through CNR2.Signal transduction and targeted therapy · 2022Article
- Cannabinoids, their cellular receptors, and effects on the invasive phenotype of carcinoma and metastasis.Cancer reports (Hoboken, N.J.) · 2022Review
- Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumArthritis research & therapy · 2022Article
- Cannabinoid receptors in the inflammatory cells of canine atopic dermatitis.Frontiers in veterinary science · 2022Article
- Pros and Cons of the Cannabinoid System in Cancer: Focus on Hematological Malignancies.Molecules (Basel, Switzerland) · 2021Review
- The Role of Extracellular Matrix Components in Inflammatory Bowel Diseases.Journal of clinical medicine · 2021Review
- Delta-9-tetrahydrocannabinol inhibits invasion of HTR8/SVneo human extravillous trophoblast cells and negatively impacts mitochondrial function.Scientific reports · 2021Article
- Cannabis and Autoimmunity: Possible Mechanisms of Action.ImmunoTargets and therapy · 2021Review
- A Synthetic Hydrogel, VitroGelFrontiers in pharmacology · 2021Article
- Inhibition of EGR-1-dependent MMP1 transcription by ethanol extract of Ageratum houstonianum in HaCaT keratinocytes.Molecular biology reports · 2021Article
- Review
- Cannabinoid Receptor 2 Modulates Maturation of Dendritic Cells and Their Capacity to Induce Hapten-Induced Contact Hypersensitivity.International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Administration of cannabinoid receptor 2 (CB2R) agonists in inflammatory and autoimmune disease and CNS injury models results in significant attenuation of clinical disease, and reduction of inflammatory mediators. Previous studies reported that CB2R signaling also reduces leukocyte migration. Migration of dendritic cells (DCs) to various sites is required for their activation and for the initiation of adaptive immune responses. Here, we report for the first time that CB2R signaling affects DC migration in vitro and in vivo, primarily through the inhibition of matrix metalloproteinase 9 (MMP-9) expression. Reduced MMP-9 production by DCs results in decreased migration to draining lymph nodes in vivo and in vitro in the matrigel migration assay. The effect on Mmp-9 expression is mediated through CB2R, resulting in reduction in cAMP levels, subsequent decrease in ERK activation, and reduced binding of c-Fos and c-Jun to Mmp-9 promoter activator protein 1 sites. We postulate that, by dampening production of MMP-9 and subsequent MMP-9-dependent DC migration, cannabinoids contribute to resolve acute inflammation and to reestablish homeostasis. Selective CB2R agonists might be valuable future therapeutic agents for the treatment of chronic inflammatory conditions by targeting activated immune cells, including DCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.